



Department of Health and Human Services
MaineCare Services
11 State House Station
Augusta, Maine 04333-0011
Tel.: (207) 287-2674; Fax: (207) 287-2675
TTY Users: Dial 711 (Maine Relay)

DUR COMMITTEE AGENDA

Date: Tuesday, October 11, 2016
Time: 12:00PM to 4:00PM
Location: Augusta Armory, 179 Western Avenue, Augusta, ME

- 1) Call to Order
- 2) MaineCare Updates
- 3) Public Comments
- 4) Old Business
 - Review of Minutes
- 5) Closed Session
 - Drug Financial Information Review
 - DUR Board Orientation (overview of DUR roles and Medicaid 101)
- 6) New Business (open session)
 - A. Present completed Retro-DUR Schedule 2017
 - B. Retro-DUR
 - Present Results - Diabetes – appropriate utilization of angiotensin modulators in patients with diabetes and hypertension
 - C. Open session to review and vote categories subject to potential changes
 - Alzheimer's Agents**
 - Analgesics, Narcotics, Long-Acting**
 - Analgesics, Narcotics, Short- Acting**
 - Androgenic Agents**
 - Angiotensin Modulators**
 - Anticoagulants**
 - Anticonvulsants**
 - Antimigraine Agents, Triptans**
 - Antiparasitics, Topical**
 - Antipsychotics**
 - Antiretrovirals**
 - Bronchodilators, Beta Agonists**
 - Cystic Fibrosis Agents**
 - Cytokine and CAM Antagonists**
 - Epinephrine, Self-Injected**
 - Glucocorticoids, Inhaled**
 - Growth Hormones**

Hemophilia Factor
Hepatitis C Agents
Hyperuricemia & Gout
Hypoglycemics, Insulins & Related Agents
Lipotropics, Other (Non-Statins)
Lipotropics, Statins
Multiple Sclerosis Agents
Ophthalmic Antibiotics
Ophthalmic Anti-inflammatories
Ophthalmics for Allergic Conjunctivitis
Ophthalmics, Glaucoma Agents
Opiate Dependence & Overdose Treatments
Pancreatic Enzymes
Phosphate Binders
Platelet Aggregation Inhibitors
Pulmonary Antihypertensives
Stimulants & Related Agents

D. FDA Safety Alerts

FDA launches competition to spur innovative technologies to help reduce opioid overdose deaths

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm520945.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Eye Wash/Eye Irrigating Solutions Distributed by Major Pharmaceuticals and Rugby Laboratories: Recall - Microbial Contamination

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm519570.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Hyoscyamine Sulfate 0.125mg by Virtus Pharmaceuticals: Recall - Superpotent and Subpotent Test Results

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm520868.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Lamotrigine Orally Disintegrating Tablet 200 mg by Impax: Recall - Incorrect Labeling of Blister Cards

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm518486.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring Boxed Warning About Serious Risks and Death

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm518710.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Ovarian Cancer Screening Tests: Safety Communication - FDA Recommends Against Use

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm519540.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm523690.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

E. Next Meeting (Tuesday, November 8, 2016 from 5:30pm to 8:30pm)

F. Adjournment: 4:00PM